225 related articles for article (PubMed ID: 18524827)
1. Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge.
Fogg CN; Americo JL; Earl PL; Resch W; Aldaz-Carroll L; Eisenberg RJ; Cohen GH; Moss B
J Virol; 2008 Aug; 82(16):8022-9. PubMed ID: 18524827
[TBL] [Abstract][Full Text] [Related]
2. Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease.
Golden JW; Zaitseva M; Kapnick S; Fisher RW; Mikolajczyk MG; Ballantyne J; Golding H; Hooper JW
Virol J; 2011 Sep; 8():441. PubMed ID: 21933385
[TBL] [Abstract][Full Text] [Related]
3. Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge.
Lustig S; Fogg C; Whitbeck JC; Eisenberg RJ; Cohen GH; Moss B
J Virol; 2005 Nov; 79(21):13454-62. PubMed ID: 16227266
[TBL] [Abstract][Full Text] [Related]
4. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions.
Fogg C; Lustig S; Whitbeck JC; Eisenberg RJ; Cohen GH; Moss B
J Virol; 2004 Oct; 78(19):10230-7. PubMed ID: 15367588
[TBL] [Abstract][Full Text] [Related]
5. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice.
Davies DH; McCausland MM; Valdez C; Huynh D; Hernandez JE; Mu Y; Hirst S; Villarreal L; Felgner PL; Crotty S
J Virol; 2005 Sep; 79(18):11724-33. PubMed ID: 16140750
[TBL] [Abstract][Full Text] [Related]
6. Effect of the deletion of genes encoding proteins of the extracellular virion form of vaccinia virus on vaccine immunogenicity and protective effectiveness in the mouse model.
Meseda CA; Campbell J; Kumar A; Garcia AD; Merchlinsky M; Weir JP
PLoS One; 2013; 8(6):e67984. PubMed ID: 23785523
[TBL] [Abstract][Full Text] [Related]
7. Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein.
Kaever T; Meng X; Matho MH; Schlossman A; Li S; Sela-Culang I; Ofran Y; Buller M; Crump RW; Parker S; Frazier A; Crotty S; Zajonc DM; Peters B; Xiang Y
J Virol; 2014 Oct; 88(19):11339-55. PubMed ID: 25031354
[TBL] [Abstract][Full Text] [Related]
8. Short-term and longer-term protective immune responses generated by subunit vaccination with smallpox A33, B5, L1 or A27 proteins adjuvanted with aluminum hydroxide and CpG in mice challenged with vaccinia virus.
Xiao Y; Zeng Y; Schante C; Joshi SB; Buchman GW; Volkin DB; Middaugh CR; Isaacs SN
Vaccine; 2020 Aug; 38(38):6007-6018. PubMed ID: 32741672
[TBL] [Abstract][Full Text] [Related]
9. Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity.
He Y; Manischewitz J; Meseda CA; Merchlinsky M; Vassell RA; Sirota L; Berkower I; Golding H; Weiss CD
J Infect Dis; 2007 Oct; 196(7):1026-32. PubMed ID: 17763325
[TBL] [Abstract][Full Text] [Related]
10. Crystal structure of vaccinia viral A27 protein reveals a novel structure critical for its function and complex formation with A26 protein.
Chang TH; Chang SJ; Hsieh FL; Ko TP; Lin CT; Ho MR; Wang I; Hsu ST; Guo RT; Chang W; Wang AH
PLoS Pathog; 2013; 9(8):e1003563. PubMed ID: 23990784
[TBL] [Abstract][Full Text] [Related]
11. Vaccinia virus L1 binds to cell surfaces and blocks virus entry independently of glycosaminoglycans.
Foo CH; Lou H; Whitbeck JC; Ponce-de-León M; Atanasiu D; Eisenberg RJ; Cohen GH
Virology; 2009 Mar; 385(2):368-82. PubMed ID: 19162289
[TBL] [Abstract][Full Text] [Related]
12. Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization.
Shinoda K; Wyatt LS; Irvine KR; Moss B
Virol J; 2009 Mar; 6():28. PubMed ID: 19257896
[TBL] [Abstract][Full Text] [Related]
13. Disulfide bond formation at the C termini of vaccinia virus A26 and A27 proteins does not require viral redox enzymes and suppresses glycosaminoglycan-mediated cell fusion.
Ching YC; Chung CS; Huang CY; Hsia Y; Tang YL; Chang W
J Virol; 2009 Jul; 83(13):6464-76. PubMed ID: 19369327
[TBL] [Abstract][Full Text] [Related]
14. Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement.
Benhnia MR; McCausland MM; Moyron J; Laudenslager J; Granger S; Rickert S; Koriazova L; Kubo R; Kato S; Crotty S
J Virol; 2009 Feb; 83(3):1201-15. PubMed ID: 19019965
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges.
Fogg CN; Americo JL; Lustig S; Huggins JW; Smith SK; Damon I; Resch W; Earl PL; Klinman DM; Moss B
Vaccine; 2007 Apr; 25(15):2787-99. PubMed ID: 17229505
[TBL] [Abstract][Full Text] [Related]
16. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
Berhanu A; Wilson RL; Kirkwood-Watts DL; King DS; Warren TK; Lund SA; Brown LL; Krupkin AK; Vandermay E; Weimers W; Honeychurch KM; Grosenbach DW; Jones KF; Hruby DE
J Virol; 2008 Apr; 82(7):3517-29. PubMed ID: 18199639
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen.
Sakhatskyy P; Wang S; Chou TH; Lu S
Virology; 2006 Nov; 355(2):164-74. PubMed ID: 16919703
[TBL] [Abstract][Full Text] [Related]
18. A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost.
Xiao Y; Aldaz-Carroll L; Ortiz AM; Whitbeck JC; Alexander E; Lou H; Davis HL; Braciale TJ; Eisenberg RJ; Cohen GH; Isaacs SN
Vaccine; 2007 Jan; 25(7):1214-24. PubMed ID: 17098336
[TBL] [Abstract][Full Text] [Related]
19. Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge.
Clark KM; Johnson JB; Kock ND; Mizel SB; Parks GD
Virology; 2011 Oct; 419(2):97-106. PubMed ID: 21885079
[TBL] [Abstract][Full Text] [Related]
20. A Nucleic Acid-Based Orthopoxvirus Vaccine Targeting the Vaccinia Virus L1, A27, B5, and A33 Proteins Protects Rabbits against Lethal Rabbitpox Virus Aerosol Challenge.
Mucker EM; Golden JW; Hammerbeck CD; Kishimori JM; Royals M; Joselyn MD; Ballantyne J; Nalca A; Hooper JW
J Virol; 2022 Feb; 96(3):e0150421. PubMed ID: 34851148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
